About GT Biologics
GT Biologics is a company based in Shoreview (United States) founded in 2007 by Denise Kelly was acquired by 4D pharma in June 2014. GT Biologics operates in a competitive market with competitors including Novozymes, Ironwood Pharma, Evelo Biosciences, RedHill Biopharma and Alcresta, among others.
- Headquarter Shoreview, United States
- Founders Denise Kelly
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of GT Biologics
Investors in GT Biologics
GT Biologics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include 4D pharma and Aquarius Equity Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life Science focused VC firm investing in the US & UK
|
Locked | Locked | Locked | |
|
Drugs from gut bacteria are developed for multiple diseases.
|
Locked | Locked | Locked |
Investor details for GT Biologics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GT Biologics
Investment portfolio details for GT Biologics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - GT Biologics
Detailed financials for GT Biologics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Gt Biologics Comparisons
Peer comparison for GT Biologics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of GT Biologics
GT Biologics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Novozymes, Ironwood Pharma, Evelo Biosciences, RedHill Biopharma and Alcresta, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biosolutions and enzymes are developed for biotechnology applications across industries.
|
|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for inflammatory diseases, COVID-19, and cancer are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases
|
|
| Locked | Locked | Locked |
Enzyme-based products for gastrointestinal disorders are developed using immobilization technology.
|
|
| Locked | Locked | Locked |
Synbiotics are developed for simulating the gut microbiome.
|
Detailed competitors of GT Biologics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Gt Biologics
Complete news archive for GT Biologics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GT Biologics
GT Biologics was founded in 2007 and raised its 1st funding round 5 years after it was founded.
GT Biologics is headquartered in Shoreview, United States. It is registered at Shoreview, Minnesota, United States.
GT Biologics was founded in 2007 and is based in Shoreview, United States. Operations focus on the biotechnology sector, where naturally occurring human bacteria are developed into biotherapeutics targeting gastrointestinal diseases such as Crohns disease. Intellectual property has been established around specific bacterial strains. The lead product remains in preclinical development for Crohns disease treatment.
GT Biologics's top competitors include Novozymes, Ironwood Pharma and Ardelyx.
GT Biologics has 2 investors. Key investors include 4D pharma, and Aquarius Equity Partners.